Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fevipiprant plus standard of care for nasal polyposis with concomitant asthma
2018-002073-22Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fevipiprant in chronic rhinosinusitis with nasal polyps (CRSwNP) and asthma (3 arms), sponsored by Novartis. Primary endpoint: Change from baseline in Nasal Polyp Score. Started Nov 2018; status: completed.
02
Drugs
fevipiprant
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)asthma
Beyond the preview
Go deeper on 2018-002073-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002073-22.